Assay development is critical in identification and confirmation of "hits", lead optimization and generating drug candidates for development. GenScript offers a comprehensive functional in vitro assay platform, using fluorometry, radioactivity, electrophysiology and cell-based assays. We are equipped to perform high throughput screening of compound libraries and can customize primary assays, secondary assays and specificity assays for your drug development needs.
Read more »
GenScript's assay development process is based on stringent quality criteria and comprehensive controls. Equipped with state-of-the-art instruments, GenScript has developed many advanced technology platforms that include fluorometry, electrophysiology, radioactivity, and cellular assays, such as in-cell Westerns. Our scientific team has extensive experience in developing pharmacologically sensitive assays for various drug target classes that include GPCRs, kinases, and proteases. Furthermore, GenScript's scientists can skillfully integrate biochemical and cell-based assays to perform pharmacological profiling in order to improve safety and efficacy of drug candidates with quality and speed.
Notably, our comprehensive services in recombinant protein production, antibody generation, peptide synthesis, and cell line development allow you to take the advantages of our reputable in-house reagents supply to speed up assay development and compound screening projects in a reliable, reproducible, and cost-effective manner.
After the compound library screening via the primary assay, secondary assay is essential for hit confirmation and evaluation. Moreover, secondary assay can also be used to evaluate the improvement of pharmacokinetic performance following lead optimization. GenScript has developed a panel of secondary assays focusing on both biochemical and cell-based modalities. With ample expertise in screening assays, we are dedicated to deliver top-quality and fast-turnaround data analysis.
Even an efficacious candidate interacting with a therapeutic target may trigger unexpected or off-target effects in a living cell. Specificity assay is an effective method to evaluate the limitation and potential risk of a candidate compound. GenScript has developed a series of specificity assay platforms integrating biochemical and cell-based method to cover a wide range of targets. Following clients' requests to develop assay on new targets, GenScript will offer a customized service based on a feasibility study.
Facing a large compound library, GenScript can help clients convert the conventional primary assay into a high-throughput screening (HTS) format and offer an assay validation for HTS. GenScript, as a world leading bio-reagent manufacturer can meet you demand for large scale HTS reagents such as protein production and large-scale cell culture.
Tailored to client's specification, GenScript offers customizable biochemical-based and cell-based compound screening services. Our compound screening service is conducted in 96-well or 384-well plate formats based on three platforms: fluorescence, radioactivity, and in-cell Western. In addition, our patch clamp platform is equipped with QPatch-16 screening station, which can run a medium throughput screening (MTS) at about 1,000 data points per work day.
Assay grade; Q-PCR validated cell pool or single clone in any host cell, with any gene.
Engineered cell lines used for better reproducibility in an endpoint-based assay.
Largest human GPCR stable cell line and validated fluorescence or radioisotope based assays.
Peptide library capability coupled with the largest protease panel in the industry.
Take advantage of our 250+ tumor cell line library for your screening needs.